EarningsQ2 2026 Earnings Report
DE:RIG2 Q2 2026 EPS Results
Actual EPS€1.54
Consensus EPS―
Beat/Miss―
One Year Ago EPS€1.78
DE:RIG2 Q2 2026 Revenue Results
Actual Revenue€654.76M
Expected Revenue€640.67M
Beat/MissBeat by +€14.09M
YoY Revenue Growth-0.04%
Earnings Announcement Details
QuarterQ2 2026
Date08/07/2026
TimeBefore Open
Conference CallFriday, August 7, 2026
DE:RIG2 Upcoming Earnings
Chemical Works of Gedeon Richter's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:RIG2 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented strong underlying operational progress: solid constant-currency revenue growth (8.7%), a significant 21% rise in Clean EBIT on a constant-currency basis, robust biotech and CNS performance, record free cash flow, and measurable cost/ESG benefits from API consolidation. However, reported results were meaningfully impacted by FX losses (notably >HUF 32bn in Q2), a weaker General Medicines performance affected by timing and market factors, one-off impairments in Biotech, and restructuring costs. On balance, the operational wins, upgraded Clean EBIT guidance, cash generation and pipeline progress outweigh the transitory negatives driven largely by FX and one-off items, supporting a constructive outlook.Company Guidance
Strong Constant-Currency Revenue Growth
Constant-currency revenue grew 8.7% in H1 2026, in line with the company's target of high single-digit full-year growth.
Significant Clean EBIT Improvement (Constant Currency)
Clean EBIT increased 21% in the first half on a constant exchange rate basis; management upgraded 2026 Pharma Clean EBIT guidance to double-digit ("in the teens") constant-currency growth based on H1 momentum.
Reported Profitability Resilience Despite FX
Reported Clean EBIT was HUF 151.8 billion (H1), a 3% increase year-on-year despite significant FX headwinds; the company highlighted accelerating profitability trends across operating segments.
Outstanding CNS Performance
CNS was a major growth/profit driver: Vraylar grew ~19% YoY (AbbVie disclosure, nearing $2bn sales), and Richter's commercial product Reagila grew ~25% in company-reported territories, boosting royalty and own-sales contributions.
Biotechnology Upside and Rapid Growth
Biotechnology revenue rose ~30% on a constant-currency basis, driven by strong teriparatide sales and recent biosimilar launches; management expects the biotech business unit to approach break-even by next year.
Record Free Cash Flow and Strong Cash Conversion
The company reported record-high free cash flow in H1; net working capital contributed positively to operating cash flow, and CapEx was controlled at HUF 10 billion in H1.
Operational and Cost Efficiency Gains
Operating expenses decreased ~6% in H1 (S&M -7%, R&D -6.5%, G&A broadly flat); management attributes improving commercial efficiency and multiyear restructuring/efficiency programs to better operating leverage and faster profit growth vs revenue.
API Consolidation and ESG/Cost Benefits
API manufacturing rightsizing produced material operational benefits: overall energy use (API-related) down ~54%, hazardous waste generation down ~11.5%, and significant reduction in operational floor area (e.g., ~30,000 sqm reduction in Budapest), supporting competitiveness and lower cost base.
Product and Pipeline Milestones
New product and R&D progress: Fylrevy (E4 mono) launched in 3 markets; expanded Lenzetto geography; RGH-202 advanced to Phase II; Compound-202 (SAD) moved into Phase II; Richter now running three parallel Phase II CNS programs (including two with AbbVie).
Biosimilars Progress and Improved Loss Position
Biosimilars top-line reported significant growth; although the biosimilars P&L returned to negative in the period, the loss decreased to HUF 2 billion vs HUF 8.5 billion a year ago, indicating material improvement.
DE:RIG2 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed